A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 3, 2007, Pages 164-173

  Kivitz, Alan J ^a   Espinoza, Luis R ^b   Sherrer, Yvonne R ^c   Liu Dumaw, Maria ^d   West, Christine R ^d  

^a Altoona Center for Clinical Research   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Center for Rheumatology Immunology and Arthritis   (United States)

^d PFIZER INC   (United States)

Author keywords

celecoxib; COX 2 selective inhibitors; nonselective NSAIDs; psoriatic arthritis

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LABORATORY TEST; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SKIN ALLERGY; SKIN MANIFESTATION; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, PSORIATIC; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 36348982256     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.03.004     Document Type: Article

References (45)

1. Mease P.J. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 16 4 (2004) 366-370
2. O'Neill T., and Silman A.J. Psoriatic arthritis. Historical background and epidemiology. Baillieres Clin Rheumatol 8 2 (1994) 245-261
3. Leonard D.G., O'Duffy J.D., and Rogers R.S. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 53 8 (1978) 511-518
4. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., and Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 8 (2006) 2665-2673
5. Brockbank J.E., Schentag C., and Rosen C. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinic attendees. Arthritis Rheum 44 Suppl 9 (2001) S94
6. Gladman D.D. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 33 1 (2003) 29-37
7. Gelfand J.M., Weinstein R., Porter S.B., Neimann A.L., Berlin J.A., and Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: a population based study. Arch Dermatol 141 12 (2005) 1537-1541
8. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 200;53(4):573.
9. Rajendran C.P., Ledge S.G., Rani K.P., and Madhavan R. Psoriatic arthritis. J Assoc Physicians India 51 (2003) 1065-1068
10. Michet C.J., Mason T.G., and Mazlumzadeh M. Hip joint disease in psoriatic arthritis: risk factors and natural history. Ann Rheum Dis 64 7 (2005) 1068-1070
11. Trontzas P., Andrianakos A., Miyakis S., Pantelidou K., Vafiadou E., Garantziotou V., et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol 24 6 (2005) 583-589
12. Winterfield L.S., Menter A., Gordon K., and Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 64 Suppl 2 (2005) ii87-ii90
13. Gladman D.D., Antoni C., Mease P., Clegg D.O., and Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 Suppl 2 (2005) ii14-ii17
14. Van Voorhees A., and Dans M.J. Psoriatic Arthritis. Emedicine (2006). http://www.emedicine.com/derm/topic918.htm Available at http://www.emedicine.com/derm/topic918.htm. Accessed November 28, 2006.
15. Candia L., Marquez J., Gonzalez C., Santos A.M., Londoño J., Valle R., et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol 12 (2006) 226-229
16. Vander C.B., Hoffman I.E., Zmierczak H., Van den B.M., Kruithof E., De Rycke L., et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64 8 (2005) 1145-1149
17. Sokoll K.B., and Helliwell P.S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 28 8 (2001) 1842-1846
18. Husted J.A., Gladman D.D., Farewell V.T., and Cook R.J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45 2 (2001) 151-158
19. Veale D.J., Ritchlin C., and Fitzgerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64 Suppl 2 (2005) ii26-ii29
20. Moll J.M., and Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 32 3 (1973) 181-201
21. Jones G., Crotty M., and Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2 (2000) CD000212
22. Nash P., and Clegg D.O. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64 Suppl 2 (2005) ii74-ii77
23. Sarzi-Puttini P., Santandrea S., Boccassini L., Panni B., and Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19 1 Suppl 22 (2001) S17-S20
24. Bensen W.G., Fiechtner J.J., McMillen J.I., Zhao W.W., Yu S.S., Woods E.M., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74 11 (1999) 1095-1105
25. Dougados M., Behier J.M., Jolchine I., Calin A., van der Heijde D., Olivieri I., et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44 1 (2001) 180-185
26. Wanders A., Heijde D., Landewe R., Behier J.M., Calin A., Olivieri I., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52 6 (2005) 1756-1765
27. Ward M.M. Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?. Arthritis Rheum 52 6 (2005) 1634-1636
28. Bensen W.G., Zhao S.Z., Burke T.A., Zabinski R.A., Makuch R.W., Maurath C.J., et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 27 8 (2000) 1876-1883
29. McKenna F., Arguelles L., Burke T., Lefkowith J., and Geis G.S. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 20 1 (2002) 35-43
30. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 10 (2000) 1247-1255
31. Steinbrocker O., Traeger C., and Batterman R. Therapeutic criteria in rheumatoid arthritis. JAMA 140 (1949) 659-662
32. Mainland D., and Cooperating Clinics Committee of American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 8 (1965) 302-334
33. Ward J.R., Williams H.J., Egger M.J., Reading J.C., Boyce E., Altz-Smith M., et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 26 11 (1983) 1303-1315
34. Clegg D.O., Reda D.J., Weisman M.H., Blackburn W.D., Cush J.J., Cannon G.W., et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39 12 (1996) 2004-2012
35. Fries J.F. The assessment of disability: from first to future principles. Br J Rheumatol 22 3 Suppl (1983) 48-58
36. Blackmore M.G., Gladman D.D., Husted J., Long J.A., and Farewell V.T. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 22 5 (1995) 886-893
37. Dictionary of Rheumatic Diseases: Signs and Symptoms Vol. 1 (1988), Contact Associates International Ltd, New York
38. Ware J.E., Snow K.K., Kosinski M., and Gandek B. SF-36 Health Survey: Manual and Interpretation Guide (1993), New England Medical Center, The Health Institute, Boston, MA
39. Husted J.A., Gladman D.D., Farewell V.T., Long J.A., and Cook R.J. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 24 3 (1997) 511-517
40. Fredriksson T., and Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157 4 (1978) 238-244
41. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
42. Barkhuizen A., Steinfeld S., Robbins J., West C., Coombs J., and Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33 9 (2006) 1805-1812
43. Sieper J., Rudwaleit M., Schwank S., and May M. Comparison of celecoxib 200 mg qd and 200 mg bid with diclofenac SR 75 mg bid for the treatment of active ankylosing spondylitis over 12 weeks. [abstract]. Ann Rheum Dis 65 Suppl II (2006) 565
44. Braun J., Baraliakos X., Brandt J., and Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34 3 (2005) 178-190
45. Jones G., Crotty M., and Brooks P. Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol 36 1 (1997) 95-99